Dacryocystitis Market Size & Share – Trends Report 2032 (2024)

Dacryocystitis Market Size

Dacryocystitis Market size was valued at USD 40.6 million in 2023 and is anticipated to showcase growth at 5.2% CAGR from 2024 and 2032. Increasing prevalence of chronic and congenital dacryocystitis, growing awareness towards advanced ophthalmic treatment options, and increasing ageing population is driving the demand for dacryocystitis treatments. Additionally, availability of advanced diagnostic techniques to timely diagnose dacryocystitis has also contributed to the revenue growth in market.

Dacryocystitis is a condition marked by inflammation or infection of the lacrimal sac, a small pouch situated at the inner corner of the eye where tears gather before flowing into the nasolacrimal duct. Market covers medication and surgical devices utilized in the treatment of dacryocystitis.

Dacryocystitis Market Trends

• Advancements in imaging technologies like high-resolution ultrasound, magnetic resonance imaging, and computed tomography are enhancing the accuracy and precision of dacryocystitis diagnosis. These sophisticated imaging methods allow medical professionals to visualize the lacrimal drainage system, detect anatomical irregularities or blockages, leading to prompt identification and treatment of dacryocystitis.
  
• Rising concerns about antibiotic resistance has resulted into an increased focus on antibiotic stewardship in the treatment of dacryocystitis. Medical practitioners are implementing strategies to optimize antibiotic usage, including targeted antibiotic therapy based on microbial culture and sensitivity testing, shorter treatment periods, and combination therapy as per the requirements.
  

Dacryocystitis Market Analysis

Based on treatment, the market is segmented into surgery and medication. The medication segment is further classified into antibiotics and other medications. The surgery segment held the majority of market share in 2023 of about 62.2%.

• Surgery is a preferred treatment as it offers long-term management of the condition and high success rates. According to a January 2023 study published by National Center for Biotechnology Information, endoscopic dacryocystorhinostomy have a success rate of about 92.6%. High success rates have increased the trust of medical practitioners and patients on surgical interventions such as dacryocystorhinostomy, thereby contributing to a leading share of the segment.
  
• Moreover, advances in minimally invasive surgical approaches for treating dacryocystitis, such as endoscopic dacryocystorhinostomy and balloon dacryoplasty has also promoted increasing adoption of surgical treatments. Minimally invasive surgical approaches involve smaller incisions, reduced tissue trauma, and shorter recovery times.
  

Based on indication, the dacryocystitis market is classified into chronic dacryocystitis, acute dacryocystitis, and congenital dacryocystitis. The chronic dacryocystitis segment dominated the market with a revenue of about USD 21.6 million in 2023.

• Leading share of chronic dacryocystitis segment can be attributed to its high prevalence in comparison to acute and congenital dacryocystitis. According to the
  

2021 article of Postgraduate Medical Journal of National Academy of Medical Sciences (NAMS), chronic dacryocystitis is a more common disorder than acute dacryocystitis. The high prevalence of chronic dacryocystitis contributes to high demand for their treatment.

• Moreover, chronic dacryocystitis is often associated to persistent or recurrent symptoms, such as tear discharge, redness, and swelling. As a result, the chronic nature of the disease frequently drives the demand for effective treatment options over a longer period, thereby driving a significant revenue growth in the chronic dacryocystitis segment.
  

Based on distribution channel, the dacryocystitis market is classified into institutional sales and retail sales. The institutional sales segment secured a leading share of about 56.4% in 2023 and is anticipated to grow at 5.1% CAGR during the forecast period.

• Treatment of dacryocystitis often involves prescription medications such as antibiotics, anti-inflammatory drugs, and topical ointments, which are typically obtained through institutional sales channels.
  
• Moreover, surgical treatment for dacryocystitis is performed across inpatient facilities such as hospitals. Medical devices and supplies used in the surgical treatment of dacryocystitis including lacrimal probes, nasal endoscopes, irrigation systems are typically purchased by healthcare institutions for use in clinical settings, which contributes to the revenue growth in institutional sales segment.
  

North America dacryocystitis market accounted for 41.6% of market share in global market in 2023 and is predicted to reach USD 25.7 million by 2032.

• North America has presence of advanced treatment facilities offering minimally invasive treatment options such as endoscopic dacryocystorhinostomy and balloon dacryoplasty, which is driving an increasing number of surgical interventions in the region, thereby contributing to the overall revenue growth of market.
  
• Additionally, increasing investments in research and development for new and improved antibiotics are driving the approvals for new eye inflammation treatments (such as US FDA approval of new cyclosporine-based anti-inflammatory treatments in June 2023). Availability of new anti-inflammatory medications is driving their adoption among dacryocystitis patients, thereby driving the revenue growth in the region.
  

The U.S. dacryocystitis market was valued at USD 14.9 million in 2023 and is anticipated to grow at a CAGR of 5% over the forecast period.

• Presence of established vendors in the U.S. has eased the availability of advanced dacryocystitis treatment options such as new medication and advanced surgical supplies, thereby contributing to the revenue growth of market in the U.S.
  
• Moreover, availability of reimbursem*nt coverage for dacryocystitis treatments has further made the treatment options accessible for the patients with limited budget availability. Thus, increasing growth in the number of dacryocystitis treatments are driving the demand for medication and surgical supplies in the U.S.
  

Germany dacryocystitis market is expected to show significant growth during the forecast period.

• Increasing growth in ageing population in Germany is contributing to an increasing incidence of dacryocystitis. According to the World Bank Group, the ageing population has significantly increased in the country. In 2020, about 16% of population aged 65 and above, that increased to 22% in 2022.
  
• Furthermore, Germany has a universal healthcare system that provides comprehensive insurance coverage for medical services, including diagnosis, treatment, and surgical procedures for dacryocystitis, which is driving increasing number of treatments for dacryocystitis in the country.
  

India dacryocystitis market is anticipated to grow remarkably over the coming years.

• Government initiatives such as India Eye Health Action Plan together with universal coverage schemes such as Ayushman Bharat are increasing awareness and treatment for eye related disorders such as dacryocystitis, thereby contributing to a rapid growth of market in India.
  
• Additionally, presence of large number of generic drug manufacturers in the country are contributing to an easy availability of cost-effective generic eye drops and antibiotics in the country for the treatment of dacryocystitis. According to the Invest India, generic manufacturers in India produce around 60,000 diverse generic brands, spanning 60 therapeutic categories.
  

Dacryocystitis Market Share

The market is highly fragmented due to the presence of many established and small vendors offering generics and surgical supplies. The generic manufacturers are offering a variety of formulations and types of dacryocystitis medications. Established vendors are outsourcing the medication and surgical supplies manufacturing to the contract manufacturers based in developing countries such as India and China, to reduce the overall manufacturing cost. Furthermore, established companies have significant experience and expertise with marketing and sales of dacryocystitis treatment products, which is contributing to the leading market share of established players.

Dacryocystitis Market Companies

Prominent players operating in the dacryocystitis industry include:

• AbbVie Inc. (Allergan)
• Alcon Inc.
• Aurolab
• Bausch Health Companies Inc.
• Bayer AG
• BVM Medical Limited
• F. Hoffmann-La Roche Ltd (Genentech, Inc.)
• FCI Ophthalmics
• Gunther Weiss Scientific Glassblowing Co., Inc.
• Heart Medical Europe BV
• Kaneka Corporation
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
  

Dacryocystitis Industry News:

• In October 2023, Harrow, Inc. announced its successful conclusion of the subsequent new drug application (NDA) transfer and the introduction of five ophthalmic products, including TOBRADEX ST (tobramycin/dexamethasone ophthalmic suspension), in the U.S.
  
• In June 2021, FCI Ophthalmics announced the launch of LacriJet in the U.S. The device contains a single use injector handpiece which includes a preloaded silicone tube inside a metallic probe. The tube helps to minimize the operating time. The device is indicated for use in congenital nasolacrimal duct obstruction.
  

The dacryocystitis market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment

• Surgery
• Medication
  • Antibiotics
  • Other medications

Market, By Indication

• Chronic dacryocystitis
• Acute dacryocystitis
• Congenital dacryocystitis

Market, By Distribution channel

• Institutional sales
• Retail sales

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa

Buy Now

Premium Report Details

• Base Year: 2023
• Companies covered: 15
• Tables & Figures: 204
• Countries covered: 22
• Pages: 111